A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.

Autor: Symonds L; Medical Oncology, University of Washington, Seattle, WA., Jenkins I; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Linden HM; Medical Oncology, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Kurland B; eResearch Technologies, Inc., Pittsburgh, PA., Gralow JR; Medical Oncology, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Gadi VVK; Medical Oncology, University of Illinois Cancer Center, Chicago, IL., Ellis GK; Medical Oncology, University of Washington, Seattle, WA., Wu Q; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Rodler E; Hematology and Oncology, University of California Davis, Sacramento, CA., Chalasani P; Hematology and Oncology, University of Arizona Cancer Center, Tucson, AZ., Chai X; Microsoft, Redmond, WA., Riedel J; Clinical Cancer Genetics, Duke Cancer Institute, Durham, NC., Scca Network Investigators; Seattle Cancer Care Alliance Network, Seattle, WA., Stopeck A; Hematology and Oncology, Stony Brook University, Stony Brook, NY., Brown-Glaberman U; Hematology and Oncology, University of New Mexico, Albuquerque, NM., Specht JM; Medical Oncology, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address: jspecht@uw.edu.

Publikováno v: Clinical breast cancer [Clin Breast Cancer] 2022 Jan; Vol. 22 (1), pp. 32-42. Date of Electronic Publication: 2021 May 24.